Innovent Biologics Secures Up to $11.4 Billion Global Collaboration Deal with Takeda
Reuters
Oct 22
Innovent Biologics Secures Up to $11.4 Billion Global Collaboration Deal with Takeda
Innovent Biologics Inc. has announced a collaboration agreement with Takeda, under which Takeda will pay Innovent an upfront payment of US$1.2 billion, including a US$100 million equity investment at a 20% premium to Innovent's 30-day weighted average share price. The total deal value may reach up to US$11.4 billion, including development and sales milestone payments for investigational medicines IBI363, IBI343, and IBI3001, as well as potential royalties. Innovent and Takeda will co-develop and co-commercialize IBI363 in the U.S., sharing development costs and profits or losses at a 40/60 split (Innovent/Takeda). Takeda will also have an exclusive option to license global rights for IBI3001 outside Greater China. Morgan Stanley Asia Limited is acting as Innovent's exclusive financial advisor for the transaction.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN03890) on October 22, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.